Positive list system faces backlash

Published: 2008-07-24 07:00:00

Updated: 2008-07-24 07:00:00

The Health Insurance Review & Assessment Service will have to re-evaluate the economic effectiveness of antihyperlipemic agents, as 20 pharmaceutical firms – Pfizer Korea, AstraZeneca Korea and Novartis Korea – asked the HIRA to re-assess its assessment.

HIRA officials said that a total of 61 ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK